EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The caspase-inhibitor Emricasan efficiently counteracts cisplatin- and neomycin-induced cytotoxicity in cochlear cells

Larissa Nassauer iD, Juliane W Schott iD, Jennifer Harre iD, Athanasia Warnecke iD, Michael Morgan iD, Melanie Galla iD, Axel Schambach iD

Journal of Molecular Medicine · 2024

DOI: 10.1007/s00109-024-02472-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Molecular Medicine, 2024. Verfasst von Larissa Nassauer und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Experimental Hematology, Hannover Medical School, Carl-Neuberg-Strasse 1, D-30625, Hannover, Germany. Hauptthemen laut MEDLINE: Cisplatin, Neomycin, Caspase Inhibitors. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: H2020 European Research Council, Medizinische Hochschule Hannover (MHH).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cisplatin is a chemotherapeutic agent widely used to treat solid tumors. However, it can also be highly ototoxic, resulting in high-frequency hearing loss. Cisplatin causes degeneration of hair cells (HCs) and spiral ganglion neurons (SGNs) in the inner ear, which are essential components of the hearing process and cannot be regenerated in mammals. As the affected cells primarily die by apoptosis, we tested several anti-apoptotic small molecules to protect these cells from drug-induced toxicity. We found that the general caspase inhibitor Emricasan could significantly counteract the toxic effects of cisplatin in House Ear Institute-Organ of Corti 1 (HEI-OC1) cells, phoenix auditory cells, and primary SGNs. Importantly, the anti-cytotoxic effect in neuronal cells was even more pronounced than the effect of sodium thiosulfate (STS), which is currently the only approved prevention option for cisplatin-induced ototoxicity. Finally, we tested the protective effect of Emricasan treatment in the context of another ototoxic drug, i.e., the aminoglycoside antibiotic neomycin, and again found a significant increase in cell viability when the cultures were co-treated with Emricasan. These results suggest a promising strategy to prevent ototoxicity in patients by temporarily blocking the apoptotic pathway when applying cisplatin or aminoglycoside antibiotics. Key messages Anti-apoptotic small molecules can reduce cisplatin-induced toxicity. Emricasan can effectively exert its anti-apoptotic effect on cochlear cells. Strong protection from cisplatin- and neomycin-induced cytotoxicity with Emricasan. Sodium thiosulfate and Emricasan provide similar protective effects to cisplatin-treated cells. Emricasan is more potent than sodium thiosulfate in reducing neomycin-induced cytotoxicity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CisplatinNeomycinCaspase InhibitorsAnimalsMiceApoptosisCochleaCell SurvivalHair Cells, AuditorySpiral GanglionOtotoxicityAntineoplastic AgentsCell LineCells, Cultured

Stichwörter der Autor:innen

Anti-apoptoticCaspase inhibitorCisplatinHearing lossNeomycinOtotoxicity

Substanzen

CisplatinNeomycinCaspase InhibitorsAntineoplastic Agents

Autor:innen und Institutionen

  • Institute of Experimental Hematology, Hannover Medical School, Carl-Neuberg-Strasse 1, D-30625, Hannover, Germany.
  • Department of Otorhinolaryngology, Head and Neck Surgery, Hannover Medical School, 30625, Hannover, Germany.
  • Cluster of Excellence "Hearing4all", Hannover Medical School, 30625, Hannover, Germany.
  • Institute of Experimental Hematology, Hannover Medical School, Carl-Neuberg-Strasse 1, D-30625, Hannover, Germany. galla.melanie@mh-hannover.de.
  • Institute of Experimental Hematology, Hannover Medical School, Carl-Neuberg-Strasse 1, D-30625, Hannover, Germany. Schambach.Axel@mh-hannover.de.
  • Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA, 02115, USA. Schambach.Axel@mh-hannover.de.

ORCID-Profile: Larissa Nassauer, Juliane W Schott, Jennifer Harre, Athanasia Warnecke, Michael Morgan, Melanie Galla, Axel Schambach

Förderung

  • H2020 European Research Council
  • Medizinische Hochschule Hannover (MHH)

Zitieren

APA

Nassauer, L., Schott, J. W., Harre, J., Warnecke, A., Morgan, M., Galla, M., & Schambach, A. (2024). The caspase-inhibitor Emricasan efficiently counteracts cisplatin- and neomycin-induced cytotoxicity in cochlear cells. Journal of Molecular Medicine. https://doi.org/10.1007/s00109-024-02472-2

Vancouver

Nassauer L, Schott JW, Harre J, Warnecke A, Morgan M, Galla M, et al. The caspase-inhibitor Emricasan efficiently counteracts cisplatin- and neomycin-induced cytotoxicity in cochlear cells. Journal of Molecular Medicine. 2024. doi:10.1007/s00109-024-02472-2

BibTeX
@article{Nassauer2024,
  author = {Nassauer, Larissa and Schott, Juliane W and Harre, Jennifer and Warnecke, Athanasia and Morgan, Michael and Galla, Melanie and Schambach, Axel},
  title = {The caspase-inhibitor Emricasan efficiently counteracts cisplatin- and neomycin-induced cytotoxicity in cochlear cells},
  journal = {Journal of Molecular Medicine},
  year = {2024},
  doi = {10.1007/s00109-024-02472-2}
}
Kostenlos starten →